Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where C. Jasmin is active.

Publication


Featured researches published by C. Jasmin.


BMJ | 1970

Bone Marrow Graft in Man after Conditioning by Antilymphocytic Serum

G. Mathé; J. L. Amiel; L. Schwarzenberg; J. Choay; P. Trolard; M. Schneider; M. Hayat; J. R. Schlumberger; C. Jasmin

Allogeneic bone marrow grafts carried out after previous administration of antilymphocytic serum alone were attempted in 16 patients. Of these, six had acute myeloblastic leukaemia, four acute lymphoblastic leukaemia, and one a blast cell crisis in polycythaemia vera. Ten of these patients were in an overt phase of the disease and resistant to chemotherapy, while nine had complete agranulocytosis. In five of these patients erythrocyte and leucocyte antigenic markers demonstrated the establishment of the graft. One patient had thalassaemia major, and four others had aplasia of the bone marrow, in one case due to chloramphenicol poisoning and in another to virus hepatitis. The grafts were successful in the last two patients and transformed their clinical condition. No signs of early acute secondary disease were noted in any of the patients, either when the donor had been given antilymphocytic serum or when he was untreated. The grafts had no adoptive immunotherapeutic effect on the acute leukaemia. These observations have clearly shown that antilymphocytic serum has an immunosuppressive effect in man when it is used alone.


Cancer | 1974

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

G. Mathé; L. Schwarzenberg; P. Pouillart; R. Oldham; R. Weiner; C. Jasmin; C. Rosenfeld; M. Hayat; Jean-Louis Misset; M. Musset; M. Schneider; J. L. Amiel; F. De Vassal

The preliminary results obtained with VM 26 and VP 16213 (two semisynthetic derivatives from epipodophyllotoxin) on leukemias and hematosarcomas are described. These compounds are phase M dependent, myelostatic agents whose toxicity can be controlled by intermittent administration. VM 26 proved capable of inducing regression in Hodgkins disease, reticulosarcomas, and lymphosarcomas. Its most remarkable effect was the total regression of neoplastic pleural effusions by systemic administration. VP 16213 seemed to be effective on the same hematosarcomas, but less often. Its most striking action was its oncostatic effect in acute monocytoid leukemia and in the monocytoid component of acute myelomonocytoid leukemia.


BMJ | 1973

Hydroxyurea, Leucopheresis, and Splenectomy in Chronic Myeloid Leukaemia at the Problastic Phase

L. Schwarzenberg; G. Mathé; P. Pouillart; R. Weiner; J. Locour; J. Genin; M. Schneider; Françoise De Vassal; M. Hayat; J. L. Amiel; J. R. Schlumberger; C. Jasmin; C. Rosenfeld

Forty-three patients with chronic myeloid leukaemia have been treated with hydroxyurea in order to be subjected to leucopheresis for white cell transfusions. Hydroxyurea decreases leucocytosis when it is administered and the blood granulocyte number increases soon after the drug is stopped. The survival of the patients is not different from the survival of the patients treated with conventional chemotherapy (busulphan, mitobronitol) and it is superior to the survival of patients treated with external radiotherapy or with 32P. Half of the patients were subjected to splenectomy during first remission for a phase II trial. They were not randomized, but the distribution according to age was similar in the two groups. A slight difference appears in favour of splenectomy so far as survival is concerned, but there were three post-operative deaths out of 18 patients. We conclude that a phase II trial on the value of splenectomy is indicated ethically, but that the patients should be operated on and nursed in a microbiologically controlled environment.


Cancer Chemotherapy and Pharmacology | 1979

Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.

M. Bayssas; J. Gouveia; P. Ribaud; M. Musset; F. de Vassal; Jose Luis Pico; L. de Luca; Jean-Louis Misset; D. Machover; D. Belpomme; L. Schwarzenberg; C. Jasmin; M. Hayat; G. Mathé

SummaryVindesine (VDS) has been submitted to a phase-II trial, the results of which were assessed in terms of regression induction. VDS was given weekly IV in doses of 2 mg/m2 on two consecutive days to 59 patients, 55 of whom were evaluable. A high proportion of complete (36%) and over 50% partial regressions were obtained in acute lymphoid leukemias (ALL) (overall response 63%) whatever the perceptible phase, in blastic crisis of chronic myeloid leukemia (55%), and some responses were recorded in lymphosarcoma (40%). No effect has so far been seen in acute myeloid leukemia or in Hodgkins disease. Malignant neoplasms of the immunoblastic type seem to be particularly sensitive to VDS. Continuous 48 h IV infusion can induce a remission where an IV push administration of the same dose has failed. One remarkable characteristic of VDS is the apparent absence of cross-resistance with VCR: in acute leukemic forms, 55% of patients who failed to obtain remission induction after three weekly injections of VCR (used in combination chemotherapy) achieved a complete or partial remission with VDS. The toxicity was mainly neurologic (paralytic ileus, constipation, paresthesias, loss of reflexes) and hematologic (leukopenia and thrombopenia), and was not more significant than with the other agents: four patients died of infection or hemorrhage.


Cancer Immunology, Immunotherapy | 1976

1975 current results of the first 100 cytologically typed acute lymphoid leukemia submitted to BCG active immunotherapy

G. Mathé; F. De Vassal; M. Delgado; P. Pouillart; D. Belpomme; R. Joseph; L. Schwarzenberg; J. L. Amiel; M. Schneider; A. Cattan; M. Musset; Jean-Louis Misset; C. Jasmin

SummaryThe first 100 acute lymphoid (and undifferentiated) leukemias, (of which the smears at the first presentation of the disease are still available for typing), treated successively with remission induction chemotherapy, complementary cell-reducing chemoradiotherapy and then active immunotherapy with irradiated pooled allogeneic leukemic cells and fresh Pasteur Institute BCG applied on scarifications, have been reviewed, especially in connection with BCG application.Tolerance of BCG has been good. Its application had to be stopped due to a side effect (choroiditis) in only one patient. This toxic cost is negligible compared to that of so-called maintenance chemotherapy.No subject of our first control trial started in 1963 has relapsed between 3 and 13 years.In the overall group of the 100 patients studied, no relapse has been observed after 48 months, which is quite different to the observations of frequent relapses after that time in patients submitted to maintenance chemotherapy.Moreover, second remissions are obtained in 94% of the patients who relapsed early under immunotherapy, and their life expectancy after a second remission is as high as it is after the first remission.The median of survival is longer than 5 years.The action of active immunotherapy on the immune machinery has been followed by several assays, of which the increase of null cells (which include K-cells) may be the most interesting.Several prognostic factors have been demonstrated among which are sex, the volume of the neoplasia, meningeal localizations, and the cytological types. Age has no prognostic value in immunotherapy patients, contrary to maintenance chemotherapy patients. Also the cytological types behave differently under immunotherapy and under maintenance chemotherapy. The disease-free survival of more than 85% of the microlymphoblastic patients submitted to immunotherapy is not observed in J. Bernards patients submitted to maintenance chemotherapy, which suggests that this high cure rate is due to active immunotherapy. Hence, these prognostic factors are probably factors of sensitivity to active immunotherapy. A statistical computerized study has shown that there is a link between the cytological types and other prognostic factors and that they all depend on the cytological type.Hence, our present protocol is adapted to this immunotherapy sensitivity factor. It comprises a nonrisk preimmunotherapy chemotherapy for the microlymphoblastic type, and a longer and more intensive chemotherapy for less immunotherapy sensitive types.


BMJ | 1969

Pathogen-free isolation unit — Three years' experience

M. Schneider; L. Schwarzenberg; J. L. Amiel; A. Cattan; J. R. Schlumberger; M. Hayat; F. de Vassal; C. Jasmin; C. Rosenfeld; G. Mathé

The results obtained during the first three years of a pathogen-free isolation unit containing five beds have shown that this type of unit can reduce the risk of infection in patients treated with intensive chemotherapy or in those who have granulocytopenia from various causes. It is suggested that treatment of cancer which involves these risks should be carried out routinely in sterile isolation units, and that it is urgent to build many more and much larger units.


Cancer Chemotherapy and Pharmacology | 1978

Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma

G. Mathé; M. Bayssas; J. Gouveia; D. Dantchev; P. Ribaud; D. Machover; Jean-Louis Misset; L. Schwarzenberg; C. Jasmin; M. Hayat

SummaryA phase II trial of which preliminary results are available for 22 patients indicates that aclacinomycin applied in a continuous modality induced complete and partial remission in four of nine patients with acute lymphoid leukaemia that was resistant to all previously available drugs, and in four of eight patients with stage V lymphosarcoma (leukaemic).Bone-marrow toxicity was the major side-effect.Only one patient of 20 suffered from cardiac toxicity; no one had alopoecia. This very low incidence of myocardial lesions and the absence of hair loss had been predicted, respectively, by our electron microscope study of the myocardium and the light electron microscope study of the skin of golden hamsters [7], a test that detects frequent severe myocardium and skin toxicities for adriamycin and some anthracyclin analogues such as detorubicin, which was found to be toxic in a high percentage of patients in a clinical trial conducted by the E.O.R.T.C. Clinical Screening Group [8].


Recent results in cancer research | 1980

Vindesine: A New Vinca Alkaloid

M. Bayssas; J. Gouveia; F. De Vassal; Jean-Louis Misset; L. Schwarzenberg; P. Ribaud; M. Musset; C. Jasmin; M. Hayat; G. Mathé

Vindesine (VDS) is an analogue of the vinca alkaloids. Its spectrum of antitumoral activity is similar to that of vincristine (VCR), but with milder experimental neurotoxicity, and it inhibits the polymerization of tubulin. Its terminal half-life is 24 h and its plasma clearance is intermediate between those of vinblastine (VLB) and VCR. The maximal tolerated dose is 4-5 mg/m2/week, the dose-limiting toxicity being myelosuppression (nadir by days 7-8 and recovery by days 11-13). It has already been demonstrated as efficient in childhood acute lymphoid leukemia (ALL), non-Hodgkins lymphoma, blastic crisis of chronic myeloid leukemia, and esophageal carcinoma. It has also shown activity in Hodgkins disease, breast and germ cell carcinomas, and melanoma. Intolerance is mainly neurologic, with paresthesias, without motor impairment, or hematologic, with leukopenia, and sometimes alopecia, asthenia, and muscle pains. The results are better if the patients have not been treated previously; continuous infusion could be of interest and there appears to be no cross-resistance with its parent VCR, as documented in ALL.


Recent results in cancer research | 1979

Dynamic and Composition of Cellular Membranes and Serum Lipids in Malignant Disorders

C. Rosenfeld; C. Jasmin; G. Mathé; M. Inbar

The dynamic structural organization of the surface membrane in mammalian cells is now widely accepted and in some cases even well-documented. However, the general term “membrane fluidity” commonly employed in this respect is actually complex and covers different properties of the membrane. The most prominent of these are: (a) the degree of lateral and rotational mobilities of membrane protein receptors [9,22] and (b) the degree of viscosity of the surface membrane lipid core [6, 7, 10, 20]. These dynamic features of the cell surface membrane, which to some extent are interrelated [21], are now believed to play a major role in cellular control mechanisms that determine normal and abnormal cell growth and differentiation [2, 3, 8, 11, 15]. Moreover, since by definition, all membrane protein receptors are embedded to some extent in the membrane lipid core, the dynamic nature or the lipid domain that is determined by its lipid composition may determine to a large extent functional activities of proteins that are embedded in it.


Archive | 1974

Attempts at Immunotherapy of 100 Acute Lymphoid Leukemia Patients: Some Factors Influencing Results

G. Mathé; P. Pouillart; L. Schwarzenberg; R. Weiner; Henry Rappaport; M. Hayat; F. de Vassal; J. L. Amiel; M. Schneider; C. Jasmin; C. Rosenfeld

There is an extensive literature on experimental active immunoprevention of cancer, which is the stimulation of immune reactions before the establishment of the tumor. This stimulation can be specific, consisting of the administration of irradiated neo-plastic cells, which generally produces a moderate effect [10, 22] or it can be nonspecific, consisting of the application of one or several agents that we have called “systemic immunity adjuvants” (SIA) [13], the most widely used being BCG injected intravenously [2, 4, 21, 26]. A marked effect is generally achieved by a combination of both means. Though the agents are administered by different routes, the effect of combined administration is usually much greater than that of the adjuvant given alone, which is itself superior to that of the irradiated tumor cells (ITC) [21].

Collaboration


Dive into the C. Jasmin's collaboration.

Top Co-Authors

Avatar

M. Hayat

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

L. Schwarzenberg

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

J. L. Amiel

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. Schneider

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

C. Rosenfeld

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

D. Machover

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

P. Ribaud

Saint Louis University

View shared research outputs
Top Co-Authors

Avatar

F. de Vassal

Institut Gustave Roussy

View shared research outputs
Top Co-Authors

Avatar

M. Delgado

Institut Gustave Roussy

View shared research outputs
Researchain Logo
Decentralizing Knowledge